GRAIL, Inc. (GRAL): A Bull Case Theory 

We came across a bullish thesis on GRAIL, Inc. on Value investing subreddit by BombasticBillionaire. In this article, we will summarize the bulls’ thesis on GRAL. GRAIL, Inc.'s share was trading at $86.41 as of October 16th.

Grail (GRAL) is emerging as a leader in multi-cancer early detection (MCED) with its Galleri blood test, which leverages machine learning on DNA methylation patterns to detect signals from over 50 cancer types, including hard-to-screen cancers like pancreatic and ovarian. The company, originally acquired by Illumina for $8 billion in 2020,...